[Federal Register Volume 59, Number 228 (Tuesday, November 29, 1994)] [Unknown Section] [Page 0] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 94-29343] [[Page Unknown]] [Federal Register: November 29, 1994] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Application Pursuant to Section 1301.43(a) of Title 21 of Code of Federal Regulations (CFR), this is notice that on September 22, 1994, Isotec, Inc. 3858 Benner Road, Miamisburg, Ohio 45342, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basis classes of controlled substances listed below: ------------------------------------------------------------------------ Drug Schedule ------------------------------------------------------------------------ Cathinone (1235)............................................ I Methcathinone (1237)........................................ I N-Ethylamphetamine (1475)................................... I N,N-Dimethylamphetamine (1480).............................. I Aminorex (1585)............................................. I Methagualone (2565)......................................... I Ktsergic acid diethylamide (7315)........................... I Tetrahydrocannabinols (7370)................................ I Mescaline (7381)............................................ I 2,5-Dimethoxyamphetamine (7396)............................. I 3,4-Methylenedioxyamphetamine (7400)........................ I 3,4-Methylenedioxy-N-ethylamphetamine (7404)................ I 3,4-Methylenedioxy- methamephetamine (7405)................. I 4-Methoxyamphetamine (7411)................................. I N-Ethyl-1-phenylcyclohexylamine (7455)...................... I Dihydromorphine (9145)...................................... I Heroin (9200)............................................... I Normorphine (9313).......................................... I Acetylmethadol (9601)....................................... I Alphacetylethadol Except Levo-Alphacetylmethadol (9603)..... I Normethadone (9635)......................................... I 3-Methylfentanyl (9813)..................................... II Amphetamine (1100).......................................... II Methamphetamine (1105)...................................... II Methylphenidate (1724)...................................... II Amobarbital (2125).......................................... II Pentobarbital (2270)........................................ II Secobarbital (2315)......................................... II 1-Phenylcyclohexylamine (7460).............................. II Phencyclidine (7471)........................................ II Phenylacetone (8501)........................................ II 1-Piperidinocyclohexane- carbonitrile (8603)................ II Codeine (9050).............................................. II Dihydrocodeine (9120)....................................... II Oxycodone (9143)............................................ II Hydromorphone (9150)........................................ II Benzoylecgonine (9180)...................................... II Ethylmorphine (9190)........................................ II Hydrocodone (9193).......................................... II Isomethadone (9226)......................................... II Meperidine (9230)........................................... II Methadone (9250)............................................ II Methadone intermediate (9254)............................... II Dextropropoxyphene, bulk (non-dosage forms) (9273).......... II Morphine (9300)............................................. II Levo-Alphacetylmethadol (9648).............................. II Oxymorphone (9652).......................................... II Fentanyl (9801)............................................. II ------------------------------------------------------------------------ The firm plans to use small quantities of the listed controlled substances to produce standards for analytical laboratories. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application and may also file a written request for a hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribed by 21 CFR 1316.47. Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than December 29, 1994. Dated: November 21, 1994. Gene R. Haislip, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 94-29343 Filed 11-28-94; 8:45 am] BILLING CODE 4410-09-M